CURRENT CONFERENCE


Joint CVG/Therapeutic Products Directorate (TPD)
2004 INTERNATIONAL CONVENTION AND EXHIBITIONS


" Active pharmaceutical ingredient to drug product:
Global issues from Scientific and regulatory Perspectives "


September 27-28, 2004 (Toronto, Ontario, Canada)
Double Tree International Plaza Hotel, 655 Dixon Road, Toronto
Tel: 416-244-1711,

This convention will be conducted in English.

September 27, 2004 - Plenary Session
Registration   8:00AM - 9:00AM
Vendor Exhibits   8:30AM - 4:00PM
Opening Remarks Dr. Herman Lam, Ph.D.
President
Calibration & Validation Group
9:00AM - 9:10AM
Key Note Address: Regulatory Challenges in the Quality Arena Sultan Ghani, TPD
Health Canada
9:10AM - 9:30AM
Selection of the Best Candidate for Active Pharmaceutical Ingredients Elizabeth Vadas, Ph.D.
In SciTech Inc.
9:30AM - 10:15AM
Morning Break All 10:15AM - 10:45AM
Regulatory Requirements in Canada for Active Pharmaceutical Ingredients Alison Ingham, Ph.D. TPD
Health Canada
10:45AM - 11:15AM
Flexible Monograph for API Karen Russo USP 11:15AM - 12:00PM
Lunch Break All 12:00PM - 2:00PM
Physical Properties Characterization of API Bernie Olsen, Ph.D.
Eli Lilly and Company
2:00PM - 2:45PM
Analytical Validation for API and Reference Standards for Early Drug Development Stephen Houldworth, Ph.D.
Dalton Chemicals
2:45PM - 3:30PM
Afternoon Break All 3:30PM - 4:00PM
Implementation of Q7A in Canada Matthew Bown, HPFBI
Health Canada
4:00PM - 4:30PM
API Manufacture in India Dr. N. Chodankar
Sekhsaria Chemicals
4:30PM - 5:00PM
Conclusion of Day 1    
Exhibition Analytical Instruments, Lab Supplies & API Suppliers 6:00PM - 7:30PM
 
September 28, 2004 - AM Morning Sessions
The Current Status of API Development in P.R.China David He, Ph.D.
Molcan Corporation
9:00AM - 9:45AM
New Source of an API-Regulatory and Scientific Challenges
(an FDA viewpoint)
Paul Schwartz, Ph.D. FDA 9:45AM - 10:30PM
Break All 10:15AM - 10:45AM
Organic Volatile Impurities (OVI) Analysis Geoff Carr, Ph.D. Patheon Inc. 10:45AM - 11:30AM
Polymorphs in API and Implications in Drug Development Steve Byrn, Professor
Purdue University
11:30AM - 12:15PM
Lunch Break All 12:15PM - 1:30PM
 
September 28, 2004 Round Table Parallel Discussion Sessions

Session 1: Pharmacopoeial
Chair/Mediator: Chung-Chow Chan, Ph.D.
Excursion Study Requirements   1:30PM - 2:00PM
Excipient Harmonization   2:00PM - 2:30PM
Break   2:30PM - 3:00PM
Starting Material for Synthetic Drug Substance 3:00PM - 3:30PM
Open Discussion   3:30PM - 4:30PM
Session 2: Equipment Qualification/Validation
Chair/Mediator: Rick Jairam
Issues in Calibration of Dissolution Apparatus 1:30PM - 2:00PM
Data Back-up and Archive Strategy 2:00PM - 2:30PM
Break   2:30PM - 3:00PM
21 CFR Part 11 ERES Update 3:00PM - 3:30PM
Open Discussion   3:30PM - 4:30PM
Session 3: Pharmaceutical Analysis: HPLC Separation & Discussion
Chair/Mediator: YC Lee, Ph.D.
HPLC Column Equivalence   1:30PM - 2:00PM
Analytical Method Transfer   2:00PM - 2:30PM
Break   2:30PM - 3:00PM
Practical Experience with USP Dissolution Apparatus 3 and 4 3:00PM - 3:30PM
Open Discussion   3:30PM - 4:30PM
Session 4: Process Analytical Technology
Chair/Mediator: Herman Lam, Ph.D.
Trends in the Use of Laser-Induced Breakdown Spectroscopy for On-, In, or At-Line Process Monitoring Louis St-Onge, Ph.D.
National Research Council
1:30PM - 2:00PM
On-Line Particle Size and Shape Characterization Combined with Color Analysis for Granular Material Bruno Albano
Cambridge Controls
2:00PM - 2:30PM
Break All 2:30PM - 3:00PM
NIR Applications for PAT Perkin Elmer 3:00PM - 3:30PM
E-Nose & E-Tongue as a Development and Formulation Tool for the Pharmaceutical Industry Mr. Vincent Schmitt
Alpha MOS
3:00PM - 3:30PM
Blend Uniformity Monitoring by Thermal Effusivity Yves Roy, Ph.D.
Mathis Instruments Inc.
3:00PM - 4:00PM
Open Discussion   4:00PM - 4:30PM
Program Committee
Alison lngham, Ph.D., Therapeutic Products Directorate
Chung Chow Chan, Ph.D., EIi Lilly Canada Inc.
Elaine Vandenberg, Ph.D., GlaxoSmithKIine Canada Inc.
YC Lee, Ph.D., Patheon Inc.
Herman Lam, Ph.D., GlaxoSmithKline Canada Inc.
Steven Boyajian, Bodycote Material Testing Canada.
CVG Executive Board
Chung Chow Chan, Ph.D.
Elaine Vandenberg, Ph.D.
Gabriel Lam
Herman Lam, Ph.D.
Steve Boyajian
William Ng
Bill Agnew
Xue-Ming Zhang, Ph.D.
YC Lee, Ph.D.
Tony Cheung
Bei Wang
Exhibitors
Activation Laboratories Ltd.; Waters Canada; Alpha-1 Network Solutions Inc.; Pall Canada Ltd.; Fisher Scientific; Agilent Technologies Inc.; Smiths Detection; Chromatographic Specialties Inc.; USP (United States Pharmacopeia); mSPEC Inc.; VWR International; Perkin-Elmer Life & Analytical Sciences Canada; LabSphere Inc.; Sotax (Canada) Ltd.; LabMetrix Technologies Inc.; Life Science Inc.; ABB Inc.; London Scientific; Pharma Laser Inc.; Phenomenex; PENSA Technology Solutions Inc.; Mathis Instruments; ATS Scientific Inc.; Dionex Canada Ltd.; Betatek Inc.; Thermo Electron Mass Spectrometry and Chromatography; Rose Scientific Ltd.; Pharma Test; Spectra Research Corporation; Power Control Inc.; Millipore Corp.; BRI Biopharmaceutical Research Inc.; IONICS Mass Spectrometry Group Inc.; Rootlink Technic Inc.; Mandel Scientific Company & Mantech Associates Inc.; Bodycote Materials Testing Canada Inc.; Kelly Scientific Resources; Mettler Toledo; BASF Canada; Varian Canada Inc.; Caledon Laboratories Ltd.; SpectraLab Scientific Inc.

Copyright © CVG 2005. All Rights Reserved
Website designed by TereDesign